

Somaxon Pharmaceuticals

[View the current Somaxon Pharmaceuticals Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/30248-Somaxon+Pharmaceuticals.html)

(<http://www.bioportfolio.com/biocorporate/30248-Somaxon+Pharmaceuticals.html>)

Contact Details:

3721 Valley Centre Drive Suite 500

San Diego

California

92130

United States of America

Tel: 858.480.0400

Fax: 858.509.1761

Email: info@somaxon.com

Somaxon is a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology. To date, we have in-licensed three products. Our lead product, SILENOR™ (doxepin HCl), is in Phase III clinical trials for the treatment of insomnia. Our product nalmefene HCl is in a Phase II/III clinical trial for the treatment of pathological gambling and a Phase II clinical trial for smoking cessation. We are also developing a new formulation of acamprosate Ca for the treatment of certain movement disorders.

We intend to continue to build a portfolio of product candidates that target psychiatric and neurological diseases and disorders, focusing on products that are currently commercialized outside the United States, approved in the United States but with significant commercial potential for proprietary new uses, new dosages or alternative delivery systems, or in late stages of clinical development .

Somaxon is a leading specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates in the fields of psychiatry and neurology. We intend to continue to build a portfolio of product candidates that target psychiatric and neurological diseases and disorders, focusing on products that are currently commercialized outside the United States, approved in the United States but with significant commercial potential for proprietary new uses, new dosages or alternative delivery systems, or in late stages of clinical development.

Recent Publications by Somaxon Pharmaceuticals:



- [The sleep of African Americans: a comparative review.](#)

*Researchers have not thoroughly assessed the sleep of African Americans...*29th September, 2006

Somaxon Pharmaceuticals, Inc., San Diego, CA 92130, USA.- Behav Sleep Med. 2006;4(1):29-44. (

[DOI Direct Link](#))

- [Biotech Mailbag: Cell Thera-Pew-Tics](#)
TheStreet.com: Jan 2 2009 4:52PM Matching: somaxon pharmaceuticals
- [Somaxon Pharmaceuticals, Inc](#)
Morningstar.com: Dec 9 2008 7:47PM Matching: somaxon pharmaceuticals
- [Somaxon Pharmaceuticals to Present at the RBC Capital Markets Healthcare Conference](#)
Freshnews.com: Dec 3 2008 5:59PM Matching: somaxon pharmaceuticals
- [Somaxon Pharmaceuticals to Present at the RBC Capital Markets Healthcare Conference](#)
DiGiTAL50: Dec 3 2008 8:41PM Matching: somaxon pharmaceuticals
- [Somaxon Pharmaceuticals to Present at the RBC Capital Markets Healthcare Conference](#)
PR inside: Dec 3 2008 2:57PM Matching: somaxon pharmaceuticals
- [Zacks Analyst Blog Highlights: Mack-Cali Realty Corp., Somaxon Pharmaceuticals, Inc., Syngenta AG, TOTAL and P](#)
DiGiTAL50: Nov 28 2008 11:38PM Matching: somaxon pharmaceuticals
- [Zacks Analyst Blog Highlights: Mack-Cali Realty Corp., Somaxon Pharmaceuticals, Inc., Syngenta AG, TOTAL and P](#)
Earthtimes.org: Nov 28 2008 11:33AM Matching: somaxon pharmaceuticals
- [Zacks Analyst Blog Highlights: Mack-Cali Realty Corp., Somaxon Pharmaceuticals, Inc., Syngenta](#)
Forbes.com: Nov 28 2008 11:51AM Matching: somaxon pharmaceuticals
- [Zacks Analyst Blog Highlights: Mack-Cali Realty Corp., Somaxon Pharmaceuticals, Inc., Syngenta AG, TOTAL and P](#)
Yahoo! Canada: Nov 28 2008 11:05AM Matching: somaxon pharmaceuticals
- [FDA Extends Review of Somaxon Pharmaceuticals' New Drug Application for Silenor by up to Three Months](#)
ComplianceHome: Nov 26 2008 7:36PM Matching: somaxon pharmaceuticals
- [BRIEF-Somaxon Pharma says FDA extends NDA review of insomnia drug](#)
Sharewatch: Nov 24 2008 1:25PM Matching: somaxon pharmaceuticals
- [UPDATE 1-FDA extends Somaxon's insomnia drug review by 3 months](#)
Sharewatch: Nov 24 2008 1:47PM Matching: somaxon pharmaceuticals
- [FDA Extends Review of Somaxon Pharmaceuticals' New Drug Application for Silenor \(Doxepin\) by up to Three Month](#)
Pharma Live: Nov 24 2008 2:56PM Matching: somaxon pharmaceuticals
- [BRIEF-Somaxon Pharmaceuticals reports Q3 results](#)
Sharewatch: Nov 6 2008 9:34PM Matching: somaxon pharmaceuticals

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo

- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.

